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A BS TR AC T
Background
Hydroxyethyl starch (HES) is widely used for fluid resuscitation in intensive care 
units (ICUs), but its safety and efficacy have not been established in patients with 
severe sepsis.
Methods
In this multicenter, parallel-group, blinded trial, we randomly assigned patients 
with severe sepsis to fluid resuscitation in the ICU with either 6% HES 130/0.42 
(Tetraspan) or Ringer’s acetate at a dose of up to 33 ml per kilogram of ideal body 
weight per day. The primary outcome measure was either death or end-stage kidney 
failure (dependence on dialysis) at 90 days after randomization.
RESULTS
Of the 804 patients who underwent randomization, 798 were included in the modi-
fied intention-to-treat population. The two intervention groups had similar baseline 
characteristics. At 90 days after randomization, 201 of 398 patients (51%) assigned 
to HES 130/0.42 had died, as compared with 172 of 400 patients (43%) assigned to 
Ringer’s acetate (relative risk, 1.17; 95% confidence interval [CI], 1.01 to 1.36; 
P = 0.03); 1 patient in each group had end-stage kidney failure. In the 90-day period, 
87 patients (22%) assigned to HES 130/0.42 were treated with renal-replacement 
therapy versus 65 patients (16%) assigned to Ringer’s acetate (relative risk, 1.35; 95% 
CI, 1.01 to 1.80; P = 0.04), and 38 patients (10%) and 25 patients (6%), respectively, 
had severe bleeding (relative risk, 1.52; 95% CI, 0.94 to 2.48; P = 0.09). The results 
were supported by multivariate analyses, with adjustment for known risk factors for 
death or acute kidney injury at baseline.
CONCLUSIONS
Patients with severe sepsis assigned to fluid resuscitation with HES 130/0.42 had an 
increased risk of death at day 90 and were more likely to require renal-replacement 
therapy, as compared with those receiving Ringer’s acetate. (Funded by the Danish 
Research Council and others; 6S ClinicalTrials.gov number, NCT00962156.)
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Intravenous fluids are the mainstay of treatment for patients with hypovolemia due to severe sepsis. Colloid solutions are used 
to obtain rapid and lasting circulatory stabiliza-
tion, but there are limited data to support this 
practice.1 The Surviving Sepsis Campaign guide-
lines recommend the use of either colloids or 
crystalloids,2 but high-molecular-weight hydroxy-
ethyl starch (HES) may cause acute kidney failure 
in patients with severe sepsis, as observed in two 
randomized trials.3,4 Those trials had substantial 
limitations, and participants received HES solu-
tions with a molecular weight of 200 kD and a 
substitution ratio (the number of hydroxyethyl 
groups per glucose molecule) of more than 0.4.3,4 
These solutions have largely been replaced by 
HES solutions with a lower molecular weight and 
a lower substitution ratio, HES 130/0.4.5,6 There 
are limited data about the effects of HES 130/0.4 
in patients with severe sepsis,7 and its routine use 
has recently been discouraged.8
Given the lack of efficacy data and concerns 
about safety, we conducted the Scandinavian Starch 
for Severe Sepsis/Septic Shock (6S) trial to evaluate 
the effects of HES 130/0.4 as compared with 
Ringer’s acetate on the composite outcome of 
death or end-stage kidney failure in patients with 
severe sepsis.
ME THODS
Trial Design and Oversight
Patients were screened and underwent random-
ization between December 23, 2009, and Novem-
ber 15, 2011, in Denmark, Norway, Finland, and 
Iceland after the appropriate approvals. Patients 
were screened at 26 general intensive care units 
(ICUs) in 13 university and 13 nonuniversity hos-
pitals. Written informed consent was obtained 
from patients or their legal surrogates before en-
rollment. In all cases, consent was obtained from 
the patient when possible. If consent was with-
drawn or not granted, we asked the patient or sur-
rogate for permission to continue registration of 
trial data and to use these data in the analyses. The 
protocol, including details on trial conduct and 
procedures and the statistical analysis plan, has 
been published previously 9 and is available with 
the full text of this article at NEJM.org. B. Braun 
Medical provided trial fluids to all trial sites free 
of charge. Neither the funders nor B. Braun Med-
ical had influence on the protocol, trial conduct, 
or data analyses or reporting. The steering com-
mittee vouches for the accuracy and completeness 
of the data and the analysis and the fidelity of the 
study to the protocol, and it made the decision to 
submit the manuscript for publication. The writ-
ing committee had full access to all data and wrote 
the manuscript with input from all authors. The 
trial was endorsed by the European Clinical Re-
search Infrastructures Network.
This trial was an investigator-initiated, multi-
center, blinded, stratified, parallel-group clinical 
trial with a computer-generated allocation se-
quence and centralized, blinded randomization. 
We randomly assigned patients with severe sep-
sis in a 1:1 ratio to fluid resuscitation with either 
HES 130/0.42 or Ringer’s acetate. Treatment as-
signments were concealed from patients, clini-
cians, research staff, the data monitoring and 
safety committee, the statistician, and the writing 
committee when it wrote the first draft for the 
abstract (for details, see the Supplementary Ap-
pendix, available at NEJM.org). Randomization 
was stratified according to the presence or ab-
sence of shock, the presence or absence of active 
hematologic cancer, and admission to a univer-
sity or nonuniversity hospital, because these char-
acteristics might have influenced the outcome.10,11 
The conduct of the trial and the safety of the 
participants were overseen by the data monitor-
ing and safety committee, which performed an 
interim analysis after 400 patients had under-
gone randomization.
Patients
We screened patients 18 years of age or older who 
needed fluid resuscitation in the ICU, as judged by 
the ICU clinicians, and who fulfilled the criteria 
for severe sepsis within the previous 24 hours12 
(for details, see the Supplementary Appendix). 
Patients were excluded for the reasons shown in 
Figure 1.
Interventions
Trial fluid (6% HES 130/0.42 in Ringer’s acetate 
[Tetraspan 6%, B. Braun] or Ringer’s acetate 
[Sterofundin ISO, B. Braun]; see the Supplemen-
tary Appendix for electrolyte content) was used 
when ICU clinicians judged that volume expansion 
was needed in the ICU for a maximum of 90 days. 
Trial fluid was delivered in identical bags (Ecobag, 
B. Braun), which were fully covered in custom-
made black, opaque plastic bags and sealed by 
staff members who were not involved in data reg-
istration or patient care. The maximum daily dose 
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was 33 ml per kilogram of ideal body weight (for 
details, see the Supplementary Appendix). If doses 
higher than the maximum daily dose were re-
quired, unmasked Ringer’s acetate was used, re-
gardless of the treatment assignment. In the event 
of severe bleeding, a severe allergic reaction, or 
the commencement of renal-replacement therapy 
for acute kidney injury, trial fluid was permanent-
ly stopped and 0.9% saline or Ringer’s lactate 
was given for volume expansion in the ICU until 
804 Underwent randomization
1211 Patients were assessed for eligibility
407 Were excluded
6 Were <18 yr of age
138 Underwent renal-replacement therapy
1 Underwent kidney or liver transplantation
5 Had burn injury >10% of body surface
9 Had intracranial bleeding
21 Had serum potassium >6 mmol per liter
within 6 hr before screening
25 Were included in another ICU trial
15 Withdrew from active therapy
152 Received >1000 ml of synthetic colloid
51 Were excluded because consent could
not be obtained
4 Were excluded after randomization
2 Underwent randomization without consent
2 Were excluded during the trial because
exclusion criteria were violated and no trial
fluid had been given
400 Were assigned to receive
HES 130/0.42
400 Were assigned to receive
Ringer’s acetate
92 Discontinued trial fluid
11 Were withdrawn on patient’s
or surrogate’s request
1 Was withdrawn by physician
80 Were withdrawn owing to 
bleeding or renal-replacement
therapy
124 Discontinued trial fluid
17 Were withdrawn on patient’s
or surrogate’s request
1 Was withdrawn by physician
104 Were withdrawn owing to
bleeding, allergic reaction,
or renal-replacement therapy
2 Withdrew consent for the
use of their data
398 (99.5%) Were included in 90-day
follow-up and analysis
400 (100%) Were included in 90-day
follow-up and analysis
Figure 1. Randomization and Follow-up of Study Patients.
Patients were excluded for medical reasons or if they had previously undergone randomization; if they had received 
more than 1000 ml of synthetic colloid in the previous 24 hours; if they were enrolled in another intensive care unit 
(ICU) trial of drugs with effects on circulation, renal function, or coagulation; or if consent could not be obtained. 
Sixteen patients met two exclusion criteria. Two patients were excluded after they had been randomly assigned to a 
treatment group because consent had not been obtained before randomization. Another two patients were excluded, 
as specified by the statistical analysis plan, because subsequent assessment showed that they met exclusion criteria 
and they never received trial fluid. Thus, four additional patients were randomly assigned to a study group to obtain 
the full sample size. Two patients withdrew consent for the use of their data after the end of the trial. HES denotes 
hydroxyethyl starch.
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90 days after randomization. All other interven-
tions were at the discretion of the ICU clinicians, 
and crystalloid and albumin solutions were allowed 
for indications other than volume expansion. Cri-
teria for renal-replacement therapy were not in-
cluded in the protocol.
Outcomes
The composite primary outcome was death or 
dependence on dialysis 90 days after randomiza-
tion13; the latter was defined as the use of any 
renal-replacement therapy during the period from 
86 to 94 days after randomization. In addition, 
these outcomes were analyzed separately. Second-
ary outcomes were death at 28 days; death at the 
time of the latest follow-up assessment; severe 
bleeding (defined as clinical bleeding that re-
quired 3 or more units of packed red cells within 
24 hours)14 while the patient was in the ICU; se-
vere allergic reactions; the score on the Sepsis-
related Organ Failure Assessment (SOFA), modi-
fied by excluding the Glasgow Coma Scale (Table 
S9 in the Supplementary Appendix),15 at day 5 
after randomization (the SOFA score includes sub-
scores ranging from 0 to 4 for each of five com-
ponents [circulation, lungs, liver, kidneys, and 
coagulation], with higher scores indicating more 
severe organ failure); the development of acute 
kidney injury (use of renal-replacement therapy or 
a renal SOFA score of 3 or higher after the patient 
had a renal SOFA score of 2 or lower at random-
ization) in the ICU after randomization; doubling 
of the plasma creatinine level in the ICU after 
randomization3,4; acidosis (arterial pH <7.35) in 
the ICU; and percentages of days alive without 
renal-replacement therapy, days alive without me-
chanical ventilation, and days alive out of the hos-
pital in the 90 days after randomization.
Data for the outcome measures were obtained 
by the 6S trial investigators or their delegates from 
patient files, national registries, and telephone 
contact with patients and hospitals for the 90-day 
follow-up period (not limited to the index admis-
sion). The final mortality follow-up was conducted 
on February 16, 2012, which was 90 days after 
randomization of the last patient.
Statistical Analysis
We calculated that we would need to enroll 800 
patients for the study to have 80% power to show 
an absolute between-group difference of 10 per-
centage points in the primary outcome measure 
at a two-sided alpha level of 0.05, assuming a 45% 
mortality rate6,16 and a 5% rate of dependence on 
dialysis at 90 days.17,18 During the trial, four pa-
tients were excluded after randomization (two for 
whom consent had not been obtained and two who 
met exclusion criteria and never received trial flu-
id). Four additional patients were randomly as-
signed to a study group to obtain the full sample 
(Fig. 1).19
All analyses were performed by one of the au-
thors before the breaking of the randomization 
code, according to International Conference on 
Harmonization–Good Clinical Practice guide-
lines20 and the statistical analysis plan. The analy-
ses were performed on data from the modified 
intention-to-treat population, defined as all ran-
domly assigned patients except those who could be 
excluded without the risk of bias (four patients 
who underwent randomization by mistake and 
who never received trial fluid)19 and those for 
whom we did not have consent for the use of data 
(two patients) (Fig. 1). In the per-protocol analyses, 
patients with one or more major protocol viola-
tions were excluded; see the Supplementary Ap-
pendix for definitions of the trial populations.
Data were analyzed with the use of unadjusted 
chi-square tests for binary outcome measures and 
Wilcoxon signed-rank tests for rate and ordinal 
data. We also compared the primary outcome in 
the per-protocol populations and in the predefined 
subgroups (patients with shock or acute kidney 
injury at the time of randomization) and used 
multiple logistic-regression analyses in the modi-
fied intention-to-treat population to adjust for dif-
ferences in baseline variables, including known 
risk factors for death or acute kidney injury. De-
tails on the handling of missing data are given in 
the Supplementary Appendix. All analyses were 
performed with the use of SAS software, version 
9.3. A two-sided P value of less than 0.05 was 
considered to indicate statistical significance.
R ESULT S
Study Population
The 798 patients — 398 in the HES 130/0.42 group 
(hereafter called the starch group) and 400 in the 
Ringer’s acetate group (Fig. 1) — were followed 
for at least 90 days and analyzed in the group to 
which they were assigned. Baseline characteris-
tics were similar in the two groups (Table 1, and 
Table S1 in the Supplementary Appendix).
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Table 1. Baseline Characteristics of the Patients.*
Characteristic
HES 130/0.42
(N = 398)
Ringer’s Acetate
(N = 400)
Age — yr
Median 66 67
Interquartile range 56–75 56–76
Male sex — no. (%) 239 (60) 244 (61)
Ideal body weight — kg†
Median 72 72
Interquartile range 60–80 60–80
Admitted to university hospital — no. (%) 194 (49) 188 (47)
Surgery — no. (%)‡
Emergency 114 (29) 116 (29)
Elective 34 (9) 48 (12)
Source of ICU admission — no. (%)
Emergency department 109 (27) 94 (24)
General ward 177 (44) 196 (49)
Operating or recovery room 59 (15) 54 (14)
Other ICU in the same hospital 21 (5) 14 (4)
Other hospital 32 (8) 42 (10)
Source of sepsis — no. (%)§
Lungs 212 (53) 229 (57)
Abdomen 130 (33) 133 (33)
Urinary tract 56 (14) 50 (12)
Soft tissue 38 (10) 46 (12)
Other 43 (11) 33 (8)
SAPS II — median (interquartile range)¶ 50 (40–60) 51 (39–62)
SOFA score — median (interquartile range)‖║ 7 (5–9) 7 (5–9)
Shock — no. (%)** 336 (84) 337 (84)
Acute kidney injury — no. (%)†† 142 (36) 140 (35)
Mechanical ventilation — no. (%) 240 (60) 245 (61)
* None of the differences between the two groups were significant (P>0.05). The values for the Simplified Acute Physiology 
Score (SAPS)21 II, Sepsis-related Organ Failure Assessment (SOFA)15 score, acute kidney injury, and mechanical ven-
tilation (invasive or noninvasive) pertain to the 24 hours before randomization. For additional baseline characteris-
tics, see Table S1 in the Supplementary Appendix. HES denotes hydroxyethyl starch, and ICU intensive care unit.
† Ideal body weight was calculated as estimated height in centimeters minus 100 for men and estimated height in cen-
timeters minus 105 for women.
‡ Data are shown for patients who underwent surgery during the index hospitalization but before randomization.
§ Some patients had more than one source of infection. The “other” category included sepsis from a vascular catheter–
related infection, meningitis, or endocarditis, as well as sepsis from unknown sources.
¶ SAPS II is calculated from 17 variables; scores range from 0 to 163, with higher scores indicating more severe disease. 
Data regarding 1 or 2 of the 17 variables were missing for 105 patients in the HES 130/0.42 group and 108 patients 
in the Ringer’s acetate group, so the scores for these patients are not included here.
║‖ The SOFA score includes subscores ranging from 0 to 4 for each of five components (circulation, lungs, liver, kid-
neys, and coagulation). Aggregated scores range from 0 to 20, with higher scores indicating more severe organ failure 
(Table S9 in the Supplementary Appendix). The scoring was modified because cerebral failure was not assessed. One 
of the five subscores was missing for two patients in the HES 130/0.42 group, so their scores are not included here.
** Shock at randomization was defined as a mean arterial pressure of less than 70 mm Hg, the need for ongoing treat-
ment with vasopressor or inotropic agents, or a plasma lactate level of more than 4.0 mmol per liter in the hour be-
fore randomization.
†† Acute kidney injury was defined as a renal SOFA score of 2 or higher (plasma creatinine level >1.9 mg per deciliter 
[170 µmol per liter] or urinary output <500 ml per day).
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Fluid Therapy, Use of Blood Products,  
and Circulatory Effects
Of the 798 patients, 779 (98%) received trial fluid. 
The median cumulative volume of fluid received 
was 3000 ml (interquartile range, 1507 to 5100) in 
the starch group and 3000 ml (interquartile range, 
2000 to 5750) in the Ringer’s acetate group 
(P = 0.20), equaling 44 ml per kilogram of ideal 
body weight (interquartile range, 24 to 75) and 
47 ml per kilogram (interquartile range, 25 to 76), 
respectively (P = 0.18). Seventy-seven patients (39 in 
the starch group and 38 in the Ringer’s acetate 
group) received open-label synthetic colloids in 
the ICU during the 90-day trial period. Sixty-nine 
patients (28 in the starch group and 41 in the 
Ringer’s acetate group) received trial fluid at dos-
es higher than the protocol-specified maximum 
daily dose. Only 2 patients in the starch group 
received HES 130/0.42 at a dose higher than the 
maximum daily dose recommended by the man-
ufacturer (50 ml per kilogram). Details on other 
fluid volumes and balances and protocol viola-
tions are provided in Table 2 and in the Supple-
mentary Appendix, including Tables S2 and S3.
More patients in the starch group than in the 
Ringer’s acetate group received blood products 
(relative risk, 1.20; 95% confidence interval [CI], 
1.07 to 1.36; P = 0.002), including packed red cells 
(relative risk, 1.28; 95% CI, 1.12 to 1.47; P<0.001) 
(Table 2, and Table S2 in the Supplementary Ap-
pendix). There were no significant differences be-
tween the two groups in the circulatory variables 
assessed at baseline and during the 24 hours 
after randomization (Table S4 in the Supplemen-
tary Appendix).
Outcomes
The primary outcome, death or dependence on 
dialysis at 90 days after randomization, occurred 
in 202 patients (51%) in the starch group as com-
pared with 173 patients (43%) in the Ringer’s ac-
etate group (relative risk, 1.17; 95% CI, 1.01 to 
1.36; P = 0.03). One patient in each group was de-
pendent on dialysis at day 90 (Table 3). Similar 
results were obtained in the multiple logistic- 
regression and per-protocol analyses (see the Sup-
plementary Appendix, including Table S6). The 
survival curves for the two intervention groups 
are shown in Figure 2, and Figure S1 in the Sup-
plementary Appendix. The two predefined sub-
group analyses showed no heterogeneity in the 
effect of HES 130/0.42 on the primary outcome 
in patients with shock or acute kidney injury at 
the time of randomization (Fig. 2).
More patients in the starch group than in the 
Ringer’s acetate group received renal-replacement 
therapy (Table 3). Among all patients, renal-
replacement therapy was associated with in-
creased 90-day mortality (61%, vs. 44% for those 
not receiving renal-replacement therapy; P<0.001). 
In the starch group, 38 patients (10%) had severe 
bleeding, as compared with 25 (6%) in the Ring-
er’s acetate group (relative risk, 1.52; 95% CI, 
0.94 to 2.48; P = 0.09) (Table 3).
The percentage of days alive without renal-
replacement therapy and the percentage of days 
alive and out of the hospital were lower in the 
starch group than in the Ringer’s acetate group 
(Table 3). None of the remaining secondary out-
comes differed significantly between the groups 
(Table 3), but some of the post hoc analyses of 
kidney injury and bleeding showed significant 
differences (Tables S7 and S8 in the Supplemen-
tary Appendix).
DISCUSSION
In this international, blinded, randomized trial 
of fluid resuscitation of patients with severe sep-
sis, HES 130/0.42 significantly increased the risk 
of death or dependence on dialysis at day 90, as 
compared with Ringer’s acetate. The difference 
was due to an increased risk of death at 90 days, 
because only 1 patient in each group was depen-
dent on dialysis at 90 days. HES 130/0.42 increased 
the absolute risk of death at 90 days by 8 percent-
age points, corresponding to a number needed to 
harm of 13. Similar results were observed in anal-
yses adjusted for risk factors and in the subgroups 
of patients with shock or acute kidney injury at the 
time of randomization.
The increased risk of death observed with HES 
130/0.42 in our trial is similar to that observed 
in the Efficacy of Volume Substitution and Insu-
lin Therapy in Severe Sepsis (VISEP) trial with 
HES 200/0.5,4 but that trial was not powered to 
show the difference with statistical significance. 
The separation of the survival curves occurred 
around day 20 in both trials, indicating late 
deaths induced by HES. Both trials showed that 
HES was associated with impaired kidney function 
and increased use of renal-replacement therapy, the 
negative consequences of which are well known 
and were confirmed by our data.17,22 In both trials, 
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coagulation was impaired and the use of red cells 
increased, which may have late adverse effects.23 A 
high fraction of HES is taken up and deposited in 
tissues, where it cannot be metabolized and it acts 
as a foreign body.24 Long-term toxic effects of HES 
deposition have been described in the kidney, liver, 
and bone marrow.25-27 Together, all these nega-
tive effects of HES may have caused the late deaths 
observed in our trial and in the VISEP trial.
Colloids are generally considered to be more 
potent plasma volume expanders than crystalloids. 
The natural colloid albumin is likely to have a 
plasma volume–expanding potency that is 40 per-
cent higher than that of saline,28 but the pharma-
cokinetics of HES 130/0.42 are different from those 
of albumin.24 In this large trial of masked fluid 
resuscitation with HES 130/0.42 as compared with 
Ringer’s acetate, we did not observe significant 
Table 2. Fluid Therapy before and after Randomization.*
Variable HES 130/0.42 (N = 398) Ringer’s Acetate (N = 400) P Value†
Patients Volume Received‡ Patients Volume Received‡
median
interquartile  
range median
interquartile 
range
no./total no.§ ml no./total no.§ ml
Trial fluid
Day 1¶ 374/397 1500 1000–1500 375/400 1500 1000–2000 0.09
Day 2 288/379 1500 1000–2000 307/380 1500 950–2000 0.50
Day 3 176/330 1000 500–1500 170/326 1000 500–1500 0.78
Open-label trial fluid
Day 1¶ 157/397 1500 1000–2000 177/400 1500 800–2500 0.21
Day 2 114/379 1000 500–1500 133/380 1000 500–2000 0.13
Day 3 54/329 900 500–1000 57/326 1000 500–1250 0.69
Other fluids‖
Day –1** 356/366 3500 2000–4938 370/385 3000 2000–4868 0.08
Day 1¶ 389/394 2235 1325–3197 393/396 1976 1077–3046 0.12
Day 2 373/376 2980 2143–3960 369/371 2905 2094–3780 0.50
Day 3 313/316 3150 2365–3910 315/317 3035 2183–3924 0.33
Blood products††
Day –1** 90/392 838 480–1435 88/399 600 490–1195 0.69
Day 1¶ 109/397 590 300–1100 89/400 600 490–980 0.13
Day 2 115/378 600 350–1100 78/379 526 300–1030 0.001
Day 3 81/327 500 300–980 68/326 598 300–750 0.28
Total‡‡ 243/376 1340 566–2700 204/380 1055 600–2755 0.003
* Detailed data on other fluids, blood products, and fluid balances are given in Tables S2 and S3 in the Supplementary 
Appendix.
† The Wilcoxon signed-rank test was used to compare differences in fluid volume between the starch group and the 
Ringer’s acetate group.
‡ Values are for the patients who received the intervention on the day.
§ The number of patients refers to those who received the specific solution, and the total number refers to those who 
had data registered. Total numbers that are smaller than the group totals reflect the exclusion of patients who died, 
were discharged from the ICU, or had missing data.
¶ Day 1 was from the time of randomization to the next start of the 24-hour fluid chart in the ICU; the median duration 
was 14 hours (interquartile range, 8 to 19).
‖ Other fluids included crystalloids, nutrition, water, fluid with medications, synthetic colloids, and albumin.
** Day –1 refers to the 24 hours before randomization.
†† Blood products included packed red cells, fresh-frozen plasma, and platelet concentrates.
‡‡ The values shown are cumulative data for the full trial period in the ICU, to a maximum of 90 days after randomization.
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differences in trial-fluid volumes between the 
study groups, a finding that is in line with the 
results of a smaller trial that compared HES 
130/0.4 (Voluven) with 0.9% saline in patients 
with sepsis.29 This finding and the fact that 
none of the other fluid volumes or balances dif-
fered markedly between the groups raises the 
question of whether there actually is a difference 
in potency between HES 130/0.42 and crystal-
loids in patients with severe sepsis.
The strengths of our trial include a low risk of 
bias, because group assignments were concealed 
and all trial procedures were blinded. It is rea-
sonable to assume that our results are generaliz-
able, because patients were recruited in univer-
sity and nonuniversity hospitals with the use of 
broad inclusion criteria and few exclusion criteria; 
the majority of screened patients were included. 
The trial protocol was pragmatic, with routine 
practice maintained except for fluid resuscita-
tion. In addition, most of the characteristics of 
the patients were similar to those of ICU pa-
tients with sepsis in other trials.4,30,31 We in-
cluded more patients who were in shock or me-
chanically ventilated than have other trials of fluid 
resuscitation in ICU patients with severe sep-
sis.4,31 Outcome rates in our trial were similar to 
those in previous trials with respect to severe 
bleeding,14 use of renal-replacement therapy,4,31 
and mortality.4,31
Table 3. Primary and Secondary Outcomes.*
Outcome
HES 130/0.42 
(N = 398)
Ringer’s Acetate
(N = 400)
Relative Risk
(95% CI) P Value
Primary outcome
Dead or dependent on dialysis at day 90 — no. (%) 202 (51) 173 (43) 1.17 (1.01–1.36) 0.03
Dead at day 90 — no. (%) 201 (51) 172 (43) 1.17 (1.01–1.36) 0.03
Dependent on dialysis at day 90 — no. (%) 1 (0.25) 1 (0.25) — 1.00
Secondary outcome measures
Dead at day 28 — no. (%) 154 (39) 144 (36) 1.08 (0.90–1.28) 0.43
Severe bleeding — no. (%)† 38 (10) 25 (6) 1.52 (0.94–2.48) 0.09
Severe allergic reaction — no. (%)† 1 (0.25) 0 — 0.32
SOFA score at day 5 — median (interquartile range) 6 (2–11) 6 (0–10) — 0.64
Use of renal-replacement therapy — no. (%)‡ 87 (22) 65 (16) 1.35 (1.01–1.80) 0.04
Use of renal-replacement therapy or renal SOFA  
score ≥3 — no. (%)§
129 (32) 108 (27) 1.20 (0.97–1.48) 0.10
Doubling of plasma creatinine level — no. (%)† 148 (41) 127 (35) 1.18 (0.98–1.43) 0.08
Acidosis — no. (%)†¶ 307 (77) 312 (78) 0.99 (0.92–1.06) 0.72
Alive without renal-replacement therapy — mean %  
of days‖
91 93 — 0.048
Use of mechanical ventilation — no. (%)† 325 (82) 321 (80) 1.02 (0.95–1.09) 0.61
Alive without mechanical ventilation — mean %  
of days‖
62 65 — 0.28
Alive and out of hospital — mean % of days‖ 29 34 — 0.048
* For severe bleeding and severe allergic reaction, data were missing for 1 patient in the Ringer’s acetate group. For dou-
bling of the plasma creatinine level, data were missing for 38 patients in the HES 130/0.42 group and 34 patients in the 
Ringer’s acetate group. For alive without mechanical ventilation, data were missing for 1 patient in the Ringer’s acetate 
group. CI denotes confidence interval.
† Outcomes are for patients in the ICU during the 90-day trial period.
‡ Outcomes are for patients with any form of renal-replacement therapy during the 90-day trial period.
§ Outcomes are for patients with any form of renal-replacement therapy during the 90-day trial period or with a renal 
SOFA score of 3 or higher after the patient had a renal SOFA score of 2 or lower at randomization.
¶ Acidosis was defined as an arterial pH of less than 7.35.
‖The mean percentage of days was calculated as the number of days without renal-replacement therapy or mechanical 
ventilation or the number of days out of the hospital divided by the number of days alive in the 90-day follow-up period.
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Figure 2. Time to Death and Relative Risk of the Primary Outcome.
Panel A shows the survival curves censored at day 90 for the two intervention groups in the modified intention-to-
treat population. Kaplan–Meier analysis showed that the survival time did not differ significantly between the two 
groups (P = 0.07). Panel B shows relative risks with 95% confidence intervals (CIs) for the primary outcome of death 
or dependence on dialysis at day 90 in the HES 130/0.42 group as compared with the Ringer’s acetate group, among 
all patients and in the two predefined subgroups. Shock at the time of randomization was defined as a mean arteri-
al pressure of less than 70 mm Hg, need for ongoing treatment with vasopressor or inotropic agents, or a plasma 
lactate level of more than 4.0 mmol per liter in the hour before randomization. Acute kidney injury at the time of 
randomization was defined as a renal score on the Sepsis-related Organ Failure Assessment (SOFA) of 2 or higher 
(plasma creatinine level >1.9 mg per deciliter [170 µmol per liter] or urinary output <500 ml) in the 24 hours before 
randomization. The SOFA score includes subscores ranging from 0 to 4 for each of five organ systems (circulation, 
lungs, liver, kidneys, and coagulation), with higher scores indicating more severe organ failure.
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Our trial has certain limitations. The pragmatic 
trial design did not include hemodynamic moni-
toring or cointerventions in the protocol except for 
recommendations to ask centers to follow inter-
national guidelines.2 Whether this affected the 
results cannot be assessed. We did not assess all 
cointerventions during the trial period. Because 
the trial was large, was blinded, and used strati-
fied randomization, it is less likely that any im-
balance in concomitant interventions affected the 
results. We included patients with acute kidney 
injury at the time of randomization. Their inclu-
sion is unlikely to have affected the trial results, 
because acute kidney injury occurred with equal 
frequency in the two intervention groups and 
because the effect of HES 130/0.42 did not differ 
significantly between patients with and those 
without acute kidney injury at the time of random-
ization. Seventy-seven patients were given open-
label synthetic colloids during the trial period. The 
use of these agents is unlikely to have affected the 
results, because the frequency of use was similar 
in the two intervention groups and because the 
per-protocol analyses, from which these patients 
were excluded, supported the primary analysis. 
Such protocol violations are difficult to prevent in 
multicenter trials in the ICU, and similar frequen-
cies were observed in the two other large trials 
of fluid therapy in ICU patients.4,28 Sixty-nine 
patients were given trial fluid at doses higher than 
the maximum daily dose. To limit the potential 
harm to trial participants from high volumes of 
HES, we defined the dosage a priori to be lower 
than that recommended by the manufacturers of 
HES and used ideal body weight in the dosage 
calculations. Therefore, only two patients in our 
trial received HES 130/0.42 at a dose higher than 
the maximum daily dose recommended by the 
manufacturers.
In conclusion, patients with severe sepsis who 
received fluid resuscitation with HES 130/0.42, as 
compared with those who received Ringer’s ace-
tate, had a higher risk of death at 90 days, were 
more likely to receive renal-replacement therapy, 
and had fewer days alive without renal-replacement 
therapy and fewer days alive out of the hospital.
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